Lipocine granted us patents directed to cns and liver programs

Salt lake city , june 14, 2022 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced that the united states patent and trademark office (uspto) has granted us patent 11,337,987 for "compositions and methods for treating central nervous system (cns) disorders" and us patent 11,370,811 for "testosterone dodecanoate compositions and methods of preparation and use".  "we are pleased to have new patents granted in support of our innovative programs to treat liver and cns disorders," said dr. mahesh patel, chairman, president, and ceo of lipocine.
LPCN Ratings Summary
LPCN Quant Ranking